Gastroenterology
Volume 138, Issue 1 , Pages 108-115 , January 2010

Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C

  • Maria Grazia Rumi

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • Corresponding Author InformationReprint requests Address requests for reprints to: Maria Grazia Rumi, MD, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, University of Milan, Via F. Sforza 35, 20122 Milan, Italy. fax (39) 025 032 0410
    • ,
  • Alessio Aghemo

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Gian Maria Prati

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Roberta D'Ambrosio

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Maria Francesca Donato

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Roberta Soffredini

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Ersilio Del Ninno

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy
    • ,
  • Antonio Russo

      Affiliations

    • Unit of Epidemiology and Biostatistics, San Carlo Borromeo Hospital, Milan, Italy
    • ,
  • Massimo Colombo

      Affiliations

    • A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università degli Studi di Milano, Milan, Italy

Received 22 May 2009 ,Accepted 11 August 2009.

References 

  1. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264
  2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451
  3. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 KDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12:195–202
  4. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J Interferon Cytokine Res. 2001;21:1103–1115
  5. Perry CM, Jarvis B. Peginterferon-α-2a (40 kd): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61:2263–2288
  6. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-α-2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556–567
  7. Manns MP, McHutchison JG, Gordon SC, et al. PegInterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  9. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon α-2a and peginterferon α-2b in naïve patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther. 2004;9:491–497
  10. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45:204–213
  11. Silva M. Compare trial: updated data. J Hepatol. 2008;49:288–294
  12. Di Bisceglie AM, Ghalib RH, Hamzeh F, et al. Early virologic response after peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hep. 2007;14:721–729
  13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth edition. Washington, DC: American Psychiatric Association; 1994;
  15. Chou R, Carson S, Chan BK. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. J Viral Hepat. 2008;15:551–570
  16. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593
  17. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–651
  18. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–103
  19. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960
  20. Aghemo A, Rumi MG, Prati GM, et al. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?. Hepatology. 2009;49:702–703
  21. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kd) plus ribavirin. Br J Clin Pharmacol. 2006;62:699–709
  22. von Wagner M, Huber M, Berg T, et al. Peginterferon-α-2a (40 kd) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522–527
  23. Jacobson IM, Brown RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971–981
  24. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. Gastroenterology. 2010;138:116–122
  25. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37–47
  26. Witthoeft T, Hueppe D, John C, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE Study. J Hepatol. 2008;48(Suppl 2):S315

 Conflicts of interest The authors disclose the following: Prof. Massimo Colombo: consulting: Schering-Plough, Roche, Novartis, Vertex; grant and research support: Schering-Plough, Roche, Novartis, Vertex; advisory committees: Schering-Plough, Roche, Novartis, Vertex; speaking and teaching: Schering-Plough, Roche, Novartis, Vertex. The remaining authors disclose no conflicts.

PII: S0016-5085(09)01575-3

doi: 10.1053/j.gastro.2009.08.071

Gastroenterology
Volume 138, Issue 1 , Pages 108-115 , January 2010

Article Tools

* Image Usage & Resolution